What is the Success Rate of Aortic Valve Replacement?

Aortic valve replacement is one of the most successful major heart procedures performed today, with short-term survival rates above 97% for most patients and steadily improving outcomes over the past two decades. The specific numbers vary depending on the type of procedure, the patient’s overall health, and where the surgery is performed, but the broad picture is encouraging: most people survive the operation, experience meaningful symptom relief, and can expect years of improved quality of life. The details behind those numbers, though, reveal important differences worth understanding.

How Short-Term Survival Has Improved

The clearest way to talk about “success rate” is short-term survival, usually measured as in-hospital or 30-day mortality. These numbers have dropped substantially over time. At one single center in Europe, in-hospital mortality for surgical aortic valve replacement (SAVR) fell from about 2.9% in the early 2000s to 0.7% by 2012–2017, and that improvement held even for patients over 80.¹ A national study in Spain showed a roughly 70% drop in mortality over two decades despite patients becoming older and sicker on average.² Better surgical techniques, safer anesthesia, and improved perioperative care have driven these gains.

An older, nationally representative U.S. database study reported overall in-hospital mortality of about 6.4% for aortic valve recipients, though that figure included patients who also underwent coronary artery bypass grafting at the same time, which raised mortality to roughly 8.3% versus 5% for valve-only cases.³ Contemporary studies from more recent years report isolated SAVR mortality closer to 1.5% at high-volume centers.⁴ The lesson here is that older statistics still circulating online can paint a gloomier picture than what patients actually face today.

For transcatheter aortic valve replacement (TAVR), the catheter-based alternative that avoids open-heart surgery, 30-day mortality runs around 2–3% in large registries. An analysis of nearly 100,000 transfemoral TAVR patients found 30-day mortality of about 2.2%.⁵ Keep in mind that TAVR patients historically tended to be older and sicker than surgical candidates, so these numbers represent a different risk pool.

Comparing TAVR and Surgical Replacement

For decades, open-heart surgical replacement was the only option. TAVR emerged as an alternative initially reserved for patients too frail for surgery, but it has expanded into lower-risk groups. A recent meta-analysis of randomized trials in lower-risk patients found that TAVR was associated with about a 19% lower hazard of death or disabling stroke at five years compared to surgery.⁶ Another pooled analysis confirmed lower rates of the combined outcome of death or stroke at 30 days and one year for TAVR, though when individual outcomes like stroke and heart attack were examined separately, the two approaches looked comparable.⁷

These findings do not mean TAVR is strictly better for everyone. TAVR valves are newer, so we have less data on how they perform 15 or 20 years out, a concern that matters most for younger patients who will live with their replacement valve the longest. Each approach also carries a different profile of complications, which the following sections explore.

Long-Term Survival After Aortic Valve Replacement

Short-term survival is just the first hurdle. Most patients want to know whether the procedure will buy them years of relatively normal life. The evidence here is reassuring, especially for older adults. A study of patients over 68 who were discharged after aortic valve replacement found their 10-year survival essentially matched that of age- and sex-matched people in the general population, meaning the surgery restored normal life expectancy for that group.⁸

Among patients with bicuspid aortic valves (a common congenital variant), survival after surgery tracked almost identically with the general Swedish population at one, five, and ten years. At 12 years, there was a small gap, with about 76% of patients surviving compared to 80% in the matched general population.⁹ These numbers are striking because they suggest the procedure does not just extend life compared to untreated severe aortic stenosis; it can bring survival back to something approaching what you would expect had the valve disease never developed.

Quality of Life After the Procedure

Survival statistics tell only part of the story. A procedure that keeps you alive but leaves you breathless and exhausted is not much of a success. Fortunately, both surgical and transcatheter replacement deliver substantial improvements in how patients feel. Research shows that physical functioning, vitality, and general health all improve significantly within the first year after aortic valve replacement.¹⁰

One advantage TAVR has over surgery in the early weeks is recovery speed. A systematic review found that TAVR patients reported noticeable quality-of-life improvements within the first 30 days, likely because the procedure involves no chest incision and no heart-lung machine. By the two- and five-year marks, however, quality of life was equivalent between the two approaches.¹¹ So the difference is largely about how quickly you get back to feeling well, not about the endpoint you ultimately reach.

Complications That Shape Outcomes

No valve replacement is complication-free. The types of problems differ between TAVR and surgery, and understanding them matters when weighing options.

Pacemaker Implantation

One of the more common complications after TAVR is the need for a permanent pacemaker, because the catheter-delivered valve can press on the heart’s electrical conduction system. The rate of new pacemaker placement runs about 7% after TAVR, roughly double the 3–4% rate seen after surgery.¹² Interestingly, not everyone who gets a pacemaker after TAVR ends up depending on it permanently. One study found that while almost all TAVR patients with new pacemakers relied on them in the first week, only about half still depended on the device after six months.¹³ Still, once a pacemaker is in, it stays in, and it brings its own set of long-term considerations.

Paravalvular Leak

When a replacement valve does not seal perfectly against the surrounding tissue, small amounts of blood leak around it. This is called paravalvular leak, or paravalvular regurgitation. Moderate or severe leaks have become uncommon with newer devices, occurring in fewer than 1% of balloon-expandable TAVR valves and about 3% of self-expanding ones at 30 days. Mild leak, however, remains frequent, showing up in roughly 29–36% of TAVR patients depending on device type.¹⁴

Even mild leak matters over time. A large meta-analysis found that any degree of paravalvular leak after TAVR was associated with about a 50% higher risk of death and an 80% higher risk of rehospitalization compared to patients with no leak.¹⁵ A long-running Japanese registry confirmed mild leak as an independent predictor of valve deterioration at nine years.¹⁶ This is one area where surgery has a traditional advantage: surgeons can directly sew the valve in place, and paravalvular leak rates tend to be lower.

Prosthesis-Patient Mismatch

Sometimes the replacement valve works but is too small for the patient’s body. The valve opens fully, but its opening area is not enough to meet the body’s blood-flow demands, creating persistently high pressure gradients across the valve. Severe cases of this mismatch occur in roughly 2–20% of surgical patients and carry about a 1.5- to 2-fold increase in the risk of death and heart-failure rehospitalization.¹⁷ A large meta-analysis of nearly 123,000 patients confirmed that over 25 years, patients with any degree of mismatch had significantly lower survival than those without it.¹⁸ Modern sizing strategies and a wider range of available valve sizes have helped, but this remains something your surgical team actively works to avoid.

Why the Hospital You Choose Matters

One of the strongest and most actionable predictors of outcome is how many of these procedures your hospital and your operator perform each year. For TAVR, a New England Journal of Medicine analysis found adjusted 30-day mortality was about 3.2% at the lowest-volume hospitals compared to 2.7% at the highest-volume ones.¹⁹ For operators individually, the difference was even more dramatic: those in their earliest phase of experience had nearly four times the mortality risk of the most experienced operators.²⁰

Surgical replacement shows a similar volume-outcome relationship. An analysis of over 234,000 SAVR patients found that the lowest-volume centers had more than double the odds of operative death compared to the highest-volume ones.⁴ That said, the same study noted substantial variation within volume categories and found that a hospital’s past outcomes were actually more predictive of future results than raw volume. Some lower-volume hospitals had excellent results. Still, if you are choosing where to have your valve replaced and have options, a center that performs the procedure frequently and can show strong outcomes is a reasonable priority.

Infection After Valve Replacement

Prosthetic valve endocarditis, an infection of the new valve, is rare but dangerous. Data from the PARTNER trials showed an incidence of about 5 infections per 1,000 patient-years for both TAVR and surgical valves, with no significant difference between the two approaches. Once endocarditis developed, however, the risk of death jumped more than fourfold.²¹

The type of biological valve material may also play a role. A Swedish registry study of over 21,000 patients with bioprosthetic aortic valves found that the cumulative incidence of endocarditis at 15 years was about 9.5% for bovine (cow tissue) valves versus 2.8% for porcine (pig tissue) valves, a surprisingly large difference that warrants further study.²² The reasons for this gap are not fully understood, but it is the kind of finding that might factor into valve selection discussions with your surgeon.

Mechanical Valves and the Blood Thinner Trade-Off

Bioprosthetic valves (made from animal tissue) eventually wear out, typically lasting somewhere around 10 to 20 years depending on the patient’s age and other factors. Mechanical valves, made from durable synthetic materials, can last a lifetime. The catch is that mechanical valves require lifelong anticoagulation therapy to prevent blood clots from forming on the valve. That medication, in turn, creates its own risk of bleeding.

A nationwide population-based study found that patients with mechanical aortic valves experienced stroke or blood clots at a rate of about 1.3 per 100 patient-years and major bleeding at about 2.6 per 100 patient-years. Older age and a history of prior stroke were the strongest predictors of clot-related events, while older age and prior major bleeding predicted future bleeds.²³ Newer mechanical valve designs have not eliminated this trade-off. A recent Swedish registry study comparing one newer valve design to older mechanical valves found no meaningful difference in major bleeding or clotting events over eight years.²⁴

This tension between durability and medication burden is a central consideration in valve selection, particularly for patients in their 50s and 60s who are young enough that a bioprosthetic valve might wear out but old enough to worry about decades of anticoagulation.

Options for Younger Adults

Younger patients face a unique dilemma: they need a valve that lasts as long as they do, but they also want to avoid lifelong blood thinners if possible. The Ross procedure offers an alternative. In this operation, the patient’s own pulmonary valve is moved to the aortic position and a donor valve is placed in the pulmonary spot. Because the aortic replacement is living tissue from the patient’s own body, no anticoagulation is needed, and durability can be excellent.

A long-term study of the Ross procedure in adults found in-hospital mortality of just 0.9%, with 20-year survival of about 81%, which closely matched the general population.²⁵ The trade-off is complexity: the Ross procedure is technically demanding, and the need for reintervention rises steadily in the second decade. By 20 years, about 45% of patients had required some additional procedure on either the autograft or the donor valve. That is a high reintervention rate, but when weighed against a lifetime of anticoagulation, many younger patients and their surgeons consider it a worthwhile exchange.

When a Replacement Valve Fails

Bioprosthetic valves degenerate over time, and when they do, patients face the prospect of reoperation. Here, the valve-in-valve TAVR approach has become an established alternative to repeat open-heart surgery. A catheter-based valve is placed inside the old failing bioprosthetic valve. A meta-analysis of this procedure reported a 97% procedural success rate, with 30-day mortality of about 5% and one-year mortality of about 12%.²⁶

Those mortality figures are higher than first-time valve replacement, which makes sense: patients needing redo procedures are typically older and have additional medical problems accumulated over the intervening years. Valve-in-valve TAVR also carries a higher risk of prosthesis-patient mismatch and coronary artery obstruction than either first-time TAVR or redo surgery, because the new valve is being squeezed inside the frame of the old one.²⁷ Long-term data on this second-generation use remain limited, but the existence of a viable less-invasive salvage option is itself a meaningful advance for patients facing valve failure.

Predicting Individual Risk

Surgeons use formal scoring systems to estimate each patient’s procedural risk before recommending an approach. The two most common are the EuroSCORE II and the STS (Society of Thoracic Surgeons) score, which crunch variables like age, kidney function, lung disease, and prior surgeries into a predicted mortality percentage. Both have shown reasonable accuracy. In one validation study, the actual 30-day mortality was 3.0% while the EuroSCORE II predicted 2.9% and the STS score predicted 2.1%.²⁸ These tools are imperfect, though. A meta-analysis of over 13,000 patients found that the scores performed better for surgical patients than for TAVR patients, where their discriminating ability was more modest.²⁹ The scores give a rough map, not a GPS-precise location. Your heart team will interpret them alongside imaging, frailty assessments, and clinical judgment.

Disparities in Who Gets Treated

Success rates tell you what happens to people who receive the procedure. An equally important question is who gets access to it in the first place. Research in the United States has uncovered significant disparities. In a large registry analysis, white patients made up over 91% of TAVR recipients, a proportion far higher than their share of the eligible population. Black and Hispanic patients were significantly underrepresented.³⁰ When nonwhite patients did receive TAVR, their in-hospital outcomes were comparable to white patients. However, Black and Hispanic patients had roughly 37–39% higher rates of heart-failure rehospitalization after discharge, a gap that persisted even after adjusting for socioeconomic factors.

The access problem runs deeper than individual demographics. A study of major U.S. metropolitan areas found that TAVR procedure rates dropped significantly in zip codes with lower household income, higher rates of poverty-related dual Medicaid eligibility, and greater community distress.³¹ These patterns mean that the “success rate” of aortic valve replacement is effectively zero for people who never get referred for it. Addressing that gap is an active area of health-policy research.

The Cost Picture

TAVR’s procedural costs are typically about $20,000 higher than surgery, driven largely by the price of the catheter-delivered valve itself. However, the shorter hospital stay offsets much of that initial premium. One cost-effectiveness analysis found that the total index hospitalization cost difference shrank to less than $3,000 with one valve system and was actually lower with another, because TAVR patients went home days sooner and needed less rehabilitation.³² Over a projected lifetime, follow-up costs were substantially lower for TAVR, leading to overall savings of roughly $8,000 to $10,000 per patient with a small gain in quality-adjusted survival. A separate analysis using a different self-expanding device found TAVR’s lifetime cost was higher but delivered additional quality-adjusted survival at a rate generally considered cost-effective.³³

Readmission rates add another financial layer. A national readmission database study found that 30-day readmission rates for standard endovascular TAVR and SAVR were similar, around 16–18%, but the cumulative 30-day costs including readmissions remained higher for TAVR.³⁴ These cost comparisons continue to shift as valve technology evolves and TAVR is used in younger, lower-risk patients whose recovery and durability expectations differ.